Can the endotrophin level in pulmonary fibrosis be a biomarker with differential diagnosis Endotrophin level in pulmonary fibrosis
Main Article Content
Keywords
Endotrophin, Interstitial lung disease, Pulmonary fibrosis, Plethysmography
Abstract
Aim: In this study, we aimed to investigate the possible role of endotrophin, a profibrotic byproduct of collagen VI, in the complex process of fibrosis development in the disease group with pulmonary fibrosis among interstitial lung diseases. Material and Method: When the patients' participation in the study was completed, smoking or alcohol drinking history, and family history were recorded. Their weights and heights were recorded and body mass index (BMI) was calculated. In every patient, Spirometry with bronchodilator testing, determination of single-breath DLCO, and plethysmographic measurement of thoracic gas volume and airway resistance were performed. Blood samples were obtained for the inflammation markers such as sedimentation rate, C-reactive protein (CRP), complete blood count, liver and renal function tests, and lactate dehydrogenase levels. Serum endotrophin levels were measured in all patients. Results: Thirty-five patients with interstitial lung disease who were having pulmonary fibrosis, 35 patients with interstitial lung disease without pulmonary fibrosis, and 20 control patients without any signs or symptoms of interstitial lung disease were included in the study. Age distribution was similar between groups. Fibrotic ILD group was more commonly smoker or ex-smoker compared with the non-fibrotic ILD patients or control cases. Fibrotic ILD patients were leaner, having significantly decreased total lung capacity, diffusion capacity and higher LDH levels. In comparison of 3 study groups regarding the endotrophin levels, there was a significant difference between groups. The fibrotic and non-fibrotic patient groups were compared for the Endotrophin levels and the difference was also significant. However, there was not any significant difference regarding the endotrophin levels between control cases and non-fibrotic ILD patients. Smoked cigarettes pocket x year showed a significant positive correlation and DLCO % and KCO % showed a significant negative correlation with the endotrophin levels. Conclusion: Serum endotrophin levels significantly increase in fibrotic ILD patients compared with the non-fibrotic ILD patients and control cases. Endotrophin may be suggested as a diagnostic marker in fibrotic interstitial lung diseases.
KEY WORDS: Endotrophin, Interstitial lung disease, Pulmonary fibrosis, Plethysmography
References
2. Meyer KC. Expert Rev Respir Med. Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis. 2017 May;11(5):343-359.
3. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011 Dec 3;378(9807):1949-61
4. Guo J, Yang Z, Jia Q, Bo C, Shao H, Zhang Z. Pirfenidone inhibits epithelial-mesenchymal transition and pulmonary fibrosis in the rat silicosis model. Toxicol Lett. 2019 Jan; 300:59-66.
5. Redente EF, Aguilar MA, Black BP, Edelman BL, Bahadur AN, Humphries SM, Lynch DA, Wollin L, Riches DWH. Nintedanib reduces pulmonary fibrosis in a model of rheuma-toid arthritis-associated interstitial lung disease. Am J Physiol Lung Cell Mol Physiol. 2018 Jun 1;314(6): L998-L1009.
6. Oka S, Furukawa H, Shimada K, Hayakawa H, Fukui N, Tsuchiya N, Tohma S. Serum bi-omarker analysis of collagen disease patients with acute-onset diffuse interstitial lung dis-ease.BMC Immunol. 2013 Feb 14; 14:9.
7. Cescon M, Gattazzo F, Chen P, Bonaldo P. Collagen VI at a glance. J. Cell Sci. 2015; 128:3525–3531. doi: 10.1242/jcs.169748.
8. Mereness JA, Bhattacharya S, Ren Y, Wang Q, Anderson CS, et al. Collagen VI Deficiency Results in Structural Abnormalities in the Mouse Lung. Am J Pathol. 2020 Feb;190(2):426-441.
9. Fitzgerald J, Rich C, Zhou FH, Hansen U. Three novel collagen VI chains, alpha4(VI), al-pha5(VI), and alpha6(VI). J Biol Chem. 2008; 283:20170.
10. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511–522.
11. Lamandé SR, Bateman JF. Collagen VI disorders: Insights on form and function in the ex-tracellular matrix and beyond. Matrix Biology. 2018; 71-72: 348–367.
12. Cescon M, Gattazzo F, Chen P, Bonaldo P. Collagen VI at a glance. J. Cell Sci. 2015; 128:3525–3531. doi: 10.1242/jcs.169748.
13. Specks U, Nerlich A, Colby T V, Wiest I, Timpl R. Increased expression of type VI collagen in lung fibrosis Am J Respir Crit Care Med.1995 Jun;151(6):1956-64.
14. Ucero AC, Bakiri L, Wagner E. Collagen VI-producing macrophages mediate lung fibrosis. European Respiratory Journal. 201;54:PA3862.
15. Okawa S, Unuma K, Yamada A, Aki T, Uemura K. Lipopolysaccharide induces expression of collagen VI in the rat lung J Toxicol Pathol 2015; 28: 37–41.
16. Sun K, Park J, Gupta OT, Holland WL, Auerbach P, Zhang N, et al. Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat Commun. 2014 Mar 19; 5:3485.
17. Rønnow SR, Langholm LL, Karsdal MA. et al. Endotrophin, an extracellular hormone, in combination with neoepitope markers of von Willebrand factor improves prediction of mor-tality in the ECLIPSE COPD cohort. Respir Res 2020; 21, 202.
18. Wick MR. Pathologic features of smoking-related lung diseases, with emphasis on smoking-related interstitial fibrosis and a consideration of differential diagnoses. Semin Diagn Pathol. 2018 Sep;35(5):315-323.
19. Hagmeyer L, Randerath W. Smoking-related interstitial lung disease. Dtsch Arztebl Int. 2015 Jan 23;112(4):43-50.
20. Pastre J, Plantier L, Planes C, Borie R, Nunes H, Delclaux C, Israël-Biet D. Different KCO and VA combinations exist for the same DLCO value in patients with diffuse parenchymal lung diseases. BMC Pulm Med. 2015 Sep 3; 15:100.
21. Peelen L, Wells AU, Prijs M, Blumenthal JP, van Steenwijk RP, Jonkers RE, et al. Fibrotic idiopathic interstitial pneumonias: mortality is linked to a decline in gas transfer. Respirol Carlton Vic nov. 2010;15(8):1233–1243.
22. Berend N. Respiratory disease and respiratory physiology: Putting lung function into per-spective interstitial lung disease. Respirol Carlton Vic oct. 2014;19(7):952–959.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Gulay Ilkhan, Tire Public Hospital
Department of Chest Diseases, Tire State Hospital, Izmir-TURKEY
Fatma Demirci Ucsular, Health Sciences University
Dr. Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, Chest Diseases Hospital
Hakan Celikhisar, Esrefpasa Metropolitan Municipality Hospital
Department of Chest Diseases, Esrefpasa Metropolitan Municipality Hospital
Yucel Arman, Okmeydanı Training and Research Hospital
Department of Internal Medicine, Okmeydanı Training and Research Hospital
Enver Yalnız, Health Sciences University
Health Sciences University, Dr. Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, Chest Diseases Hospital
Tufan Tukek, Okmeydanı Training and Research Hospital
Department of Internal Medicine, İstanbul University İstanbul Faculty of Medicine- Istanbul, TURKEY
How to Cite
